

## Evaluation of Risk Factors for Metachronous Liver and Lung Metastasis in Colorectal Carcinoma

Seiichiro HOSHINO, Yasushi YAMAUCHI, Kouji MIKAMI,  
Tetsuo SHINOHARA, Tomoaki NORITOMI, Takafumi MAEKAWA  
and Yuuichi YAMASHITA

*Department of Gastroenterological Surgery, Fukuoka University School of Medicine 7-45-1,  
Nanakuma, Jonan-ku, Fukuoka, Japan 814-0180*

**Abstract :** Hepatic and lung recurrences are major determinants of survival for patients who have undergone a curative resection for colorectal carcinoma. The aim of this study was to assess the risk factors of metachronous liver and lung metastases from colorectal carcinoma. **Method :** From January 1991 to April 2000, 705 patients with histologically confirmed adenocarcinoma of the colorectum and who had been operated on at our institution were retrospectively evaluated for this study. We investigated the risk factors of metachronous liver and lung metastases from colorectal carcinoma. **Results :** According to a univariate analysis, lymph node metastasis, depth of invasion, and extramural lymphatic invasion were found to have a significant influence on the incidence of metachronous liver metastasis. Based on a multivariate logistic analysis, lymph node metastasis proved to be an independent recurrent factor. On the other hand, a univariate analysis showed lymph node metastasis, depth of invasion, and extramural lymphatic invasion to have a significant influence on lung metastasis. On multivariate logistic analysis, lymph node metastasis and lymphatic invasion proved to be independent recurrent factors. **Conclusions :** Patients with not only positive results for lymph nodes metastasis but also positive results for lymphatic invasion should therefore be carefully followed and will likely be good candidates for postoperative adjuvant chemotherapy.

**Key words :** Risk factors, Colon cancer, Metachronous liver metastasis, Metachronous lung metastasis

### Introduction

Colorectal carcinoma is a worldwide public health concern and a frequent disease with increasing incidence. Its prognosis has recently improved because of the development of diagnostic and therapeutic procedures. However, optimized surgery with a curative intent may also be followed by an unfavorable course of the disease, primarily due to the occurrence of distant metastasis during the follow-up. In addition, distant metastases are the major cause of death for colorectal carcinoma patients. Patients with stage colon

carcinoma have a 5-year survival of 70-80% after curative surgery, but it is difficult to identify the 20-30% of patients who will have recurrence. For stage patients with involvement of lymph nodes, the 5-year survival rate decreases to 30-50%. Some patients with stage disease are at high risk for recurrence and receive adjuvant chemotherapy, although its benefits remain unclear.<sup>1)</sup>

Liver metastasis is the most common site of recurrence in colon cancer patients,<sup>2)</sup> and lung metastatic patients are increasing. If the metastatic disease is left untreated, the median survival is 6-12 months.<sup>3)</sup> Whereas simple analyses of factors that appear to influence survival have been re-

---

Corresponding to : Seiichirou HOSHINO, M. D.

Department of Gastroenterological Surgery, Fukuoka University School of Medicine, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, Japan 814-0180

Tel : 81-(0)92-801-1011 ext. 3425, Fax : 81-(0)92-863-9759, E-mail : shoshino@fukuoka-u.ac.jp

ported in many studies, there have been few attempts to use multivariate statistical methods to identify variables with independent effects on survival after resection of colorectal carcinoma.<sup>4)</sup> In addition, No risk factors for metachronous metastasis have been reported.

We herein report an investigation of the risk factors of metachronous liver and lung metastases from colorectal carcinoma.

### Methods

Between January 1991 and April 2000, 705 patients with histologically confirmed adenocarcinoma of the colorectum who had been operated on at our institution were retrospectively evaluated for this study. All patients had undergone colorectal surgery. The patients who could not undergo surgery due to various reasons were excluded. According to the Japanese Society for Cancer of the Colon and Rectum ( 16<sup>th</sup> Edition ), 45 patients were pathologically staged as 0, 168 as I, 197 as II, 105 as IIIa, 74 as IIIb, and 116 as IV. In 705 patients, 84 patients had synchronous liver metastasis and 31 had metachronous liver metastasis. Seventeen patients had synchronous lung metastasis and 14 had metachronous lung metastasis ( Table 1 ). The general epidemiologic data, clinical findings, treatment, histopathologic examination, and follow-up data were collected retrospectively. In this study, we evaluated the risk factors of liver metastasis and lung metastasis especially in metachronous metastasis.

The clinicopathological variables including sex, tumor gross appearance ( 1, 2 type/3, 4 type ), lymph node metastasis, tumor depth, lymphatic invasion, venous invasion, and pathological grade were analyzed. The pearson chi-square test was

used for comparison of sex, gross appearance, lymph node metastasis, tumor depth, lymphatic invasion, venous invasion and pathological grade. The Survival curves were generated by the Kaplan – Meier method. Differences in the survival rates were determined with the log – rank test. To identify independent prognostic factors for survival, multivariate analysis was performed using the Cox regression hazards model. We also used a multiple logistic regression to determine the risk factors for metachronous metastases. Level for statistical significance was set at 0.05.

### Results

The 5 – year survival rate of patients without metastasis was 87.4%. Patients with metachronous liver metastasis had significantly higher 5 – year survival rates than those with synchronous liver metastasis ( 45.1%, 8 %,  $p < 0.0001$ , Fig. 1 ). In the same way, patients with metachronous lung metastasis had significantly higher 5 – year survival rates than those with synchronous metastasis ( 92.9% , 17.5%,  $p = 0.0049$ , Fig. 2 )

The incidence of synchronous liver metastasis was 11.9% and that of metachronous liver metastasis was 4.4% . Table 1 shows the recurrent number according to each stage. In metachronous liver metastasis, the most frequent stage was found to be IIIa ( 11.4% ). The incidence of synchronous lung metastasis was 2.4% and that of metachronous lung metastasis was 2 % respectively ( Table 1 ) The most frequent stage was IIIa in metachronous lung metastasis ( 6.6% ). On univariate analysis ( Table 2 ), lymph node metastasis, depth of invasion, and extramural lymphatic invasion were found to have a significant influence on the incidence of metachronous liver metastasis. On

Table 1. Patient characteristics

| Stage | total | liver metastasis |              | lung metastasis |              |
|-------|-------|------------------|--------------|-----------------|--------------|
|       |       | synchronous      | metachronous | synchronous     | metachronous |
| 0     | 45    | 0                | 0            | 0               | 0            |
|       | 168   | 0                | 2            | 0               | 0            |
|       | 197   | 0                | 7            | 0               | 2            |
| a     | 105   | 0                | 12           | 0               | 7            |
| b     | 74    | 0                | 5            | 0               | 4            |
|       | 116   | 84               | 5            | 17              | 1            |




Fig 1. The 5-year survival rate of metachronous liver metastatic patients was 45.1% and that of synchronous liver metastatic patients was 8%. ( $p < 0.0001$ )




Fig 2. The 5-year survival rate of metachronous lung metastatic patients was 92.5% and that of synchronous liver metastatic patients was 17.5%. ( $p = 0.0049$ )

Table 2. Risk factors for metachronous liver metastasis

| metastasis         | ( - )   | ( + ) | <i>p</i> -value |
|--------------------|---------|-------|-----------------|
| gender             | 317/232 | 18/13 | 0.985           |
| gross apper ~ 2' / | 503/ 59 | 27/ 4 | 0.909           |
| n factor           | 396/142 | 11/20 | < 0.0001        |
| depth ss,a1/       | 402/103 | 15/16 | 0.003           |
| 1y factor 0/       | 94/454  | 2 /29 | 0.096           |
| v factor 0/        | 146/380 | 3 /28 | 0.024           |
| patho well/        | 355/190 | 17/14 | 0.242           |

Table 3. Risk factors for metachronous liver metastasis( multivariate analysis )

|           | odds ratio | <i>p</i> -value |
|-----------|------------|-----------------|
| n factor  | 2.849      | 0.0217          |
| depth     | 2.269      | 0.0636          |
| 1y factor | 0.959      | 0.9634          |
| v factor  | 1.439      | 0.6399          |

multivariate logistic analysis, lymph node metastasis proved to be an independent recurrent factor ( Table 3 ). On the other hand, a univariate analysis showed lymph node metastasis, depth of invasion, and extramural lymphatic invasion to have a

significant influence on lung metastasis ( Table 4 ). According to a multivariate logistic analysis, lymph node metastasis and lymphatic invasion proved to be independent recurrent factors ( Table 5 ).

Table 4. Risk factors for metachronous lung metastasis

| metastasis         | ( - )   | ( + ) | <i>p</i> -value |
|--------------------|---------|-------|-----------------|
| gender             | 317/232 | 8/ 6  | 0.938           |
| gross apper ~ 2' / | 503/ 59 | 10/ 4 | 0.520           |
| n factor           | 396/142 | 3/11  | < 0.0001        |
| depth ss, a1/      | 402/103 | 7/ 7  | 0.0313          |
| 1y factor 0/       | 94/454  | 2/12  | 0.0446          |
| v factor 0/        | 146/380 | 5/ 9  | 0.954           |
| patho well/        | 355/190 | 7/ 7  | 0.317           |

Table 5. Risk factors for metachronous lung metastasis( multivariate analysis )

|           | odds ratio | <i>p</i> -value |
|-----------|------------|-----------------|
| n factor  | 26.969     | 0.0138          |
| depth     | 2.208      | 0.3714          |
| 1y factor | 4.113      | 0.0497          |
| v factor  | 0.417      | 0.4967          |

## Discussion

Hepatic and lung metastases from colorectal carcinoma are major determinants of survival for patients who have undergone curative resection of colorectal carcinoma. Recent advances in surgery of the liver and lung have made surgical therapy common for the treatment of patients with metastases from colorectal carcinoma. Approximately 25% of patients with isolated hepatic metastases resected curatively, and 21–48% will survive for 5 years with low morbidity and mortality.<sup>3)–7)</sup> In addition, the lung is the most common extraabdominal site of metastases from colorectal carcinoma,<sup>8)</sup> and resectable metastatic disease is limited to the lung in approximately 1–2 % of patients after a resection of colorectal carcinoma.<sup>9) 10)</sup>

Previous studies have indicated the survival for colon carcinoma and risk factors after resection of metastatic liver and lung tumors to be approximately 5 years.<sup>11)</sup> To our knowledge, no previous studies have examined the risk factors for liver and lung metachronous metastasis. Liver and lung metastasis is one of the most important risk factors affecting the 5-year survival, therefore, an investigation of the risk factors for liver and lung metastasis would thus contribute significantly to an improved survival.

To date, no effective chemotherapeutic treatment is available for hepatic and lung metastases from

colorectal carcinoma. Consequently, a surgical resection of hepatic and lung metastases has been accepted as the optimal therapy by many physicians.

In our institution, we also performed surgery if the metastatic liver and lung lesion was resectable. Nevertheless, the 5-year survival rate of metachronous liver cases was confined to 45.1%. The risk factors of metachronous liver metastases were found to be lymph node metastasis, depth of invasion, and extramural lymphatic invasion on univariate analysis. According to a multivariate logistic analysis, lymph node metastasis proved to be an independent recurrent factor. Generally, lymph node metastasis is the risk factor that most affects the survival rate. The more the lymph node-positive rate increases, the more staging increases. As a result, lymph node metastasis remains as the only factor affecting the staging background.

Regarding lung metastases, lymph node metastasis and lymphatic invasion proved to be independent recurrent factors on multivariate analysis. These results must indicate that cancer cells move via lymph vessels, not via the inferior mesenteric vein. Iizasa et al. reported using clinical factors that elevated the carcinoembryonic antigen level and the quantity of metastases are thus considered to be independent prognostic factors.<sup>4)</sup> In this study, we did not examine the CEA or metastatic counts.

The 5-year survival rate of metachronous lung

cases was 92.9%, which was better than the liver metastatic survival rate. This reason for this depended not only on the small number of lung metastatic cases, but it was also due to the fact that the time of the metastasis onset was later than in liver metastatic cases.

In this series, two patients of stage and 7 of stage developed metachronous liver metastasis. Of the stage patients, 2 developed metachronous lung metastasis. These results suggest that if a patient is positive for lymphatic invasion, then a follow-up is necessary even if the stage is relatively low.

Our data revealed that lymph node metastasis is the most important risk factor for liver and lung metastasis. Lymphatic invasion was also found to be an important factor for lung metastasis. In these cases, frequent examinations will be necessary and should contribute to improving the curability rate of metastasis and the overall survival.

Positive results for lymphatic invasion and lymph nodes during a curative resection are therefore considered to be useful for selecting colorectal cancer patients at high risk for developing lung and hepatic recurrence, and for identifying who may be good candidates for postoperative adjuvant chemotherapy.

#### References

- 1 ) O'Connell MJ, Schaid DJ, Ganju V, Cunnigham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular marker play a role in predicting prognosis ? *Cancer* 70 : 1732-1739, 1992.
- 2 ) Devency KE, Way LW. Follow-up of patients with colorectal cancer. *Am. J. Surg* 148 : 717-722, 1984.
- 3 ) Luna-Perez P, Rodriguez-Coria DF, Arroyo B, Gonzalez-Macouzet J. The natural history of liver metastases from colorectal carcinoma. *Arch. Med. Res* 29 : 319-324, 1998.
- 4 ) Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. *Ann Thorac Surg*. 82 : 254-260, 2006.
- 5 ) Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastasis. *World J Surg* 19 : 59-71, 1995.
- 6 ) Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. *Cancer* 77 : 1254-1262, 1996.
- 7 ) Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. *Cancer* 71 : 4252-4266, 1993.
- 8 ) Busch E, Kemeny MM. Colorectal cancer : hepatic-directed therapy- the role of surgery, regional chemotherapy, and novel modalities. *Semin Oncol* 22 : 494-508 1995.
- 9 ) Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton, JH, Wolff, BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. *Surg Gynecol Obstet* 174 : 27-32, 1992.
- 10 ) McCormack PM, Attiyeh FF. Resected pulmonary metastases from colorectal cancer. *Dis Colon Rectum* 22 : 553-56, 1979.
- 11 ) Goya T, Miyazaki N, Kondo H, Tsuchiya R, Naruke T, Suemasu K. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. *Cancer* 64 : 1418-1421, 1989.

( Received on July 30, 2007,  
Accepted on September 20, 2007 )